by Madaline Spencer | Oct 22, 2025
The U.S. Food and Drug Administration (FDA) has approved Gazyva/Gazyvaro (obinutuzumab) for the treatment of adults with active lupus nephritis who are receiving standard of care. In addition, the approval includes a shorter 90-minute infusion time after the first...
by Madaline Spencer | Oct 20, 2025
Christelle Huguet, PhD, Head of Research and Development at Ipsen, discusses the company’s current approved orphan drugs and those in development for rare diseases. Ipsen’s work in the rare disease space aims to address areas of high unmet medical needs;...
by Madaline Spencer | Oct 17, 2025
Scott Baver, PhD, Vice President of Medical Affairs at ITF Therapeutics, discusses new data on the use of Duvyzat (givinostat) for patients with Duchenne muscular dystrophy (DMD). DMD is a rare neuromuscular disorder characterized by progressive muscle...
by Madaline Spencer | Oct 16, 2025
Jai Radhakrishnan, MD, Nephrologist and Professor at Columbia University Medical Center, discusses diagnosis and treatment of IgA nephropathy (IgAN). IgAN is an autoimmune kidney disorder characterized by the settling of IgA protein in the kidneys. In...
by Madaline Spencer | Oct 15, 2025
Giselle Saulnier Sholler, MD, Division Chief for Pediatric Hematology/Oncology at Penn State University and Founder of the Beat Childhood Cancer Research Consortium, discusses the organization’s work in neuroblastoma. Neuroblastoma is a rare cancer...
